Download PDF
Aktuelle Rheumatologie 2007; 32(3): 136-139
DOI: 10.1055/s-2007-963324
Originalarbeit

© Georg Thieme Verlag KG Stuttgart · New York

Anakinra - eine neue therapeutische Option für die systemische juvenile idiopathische Arthritis

Anakinra - a New Option for Therapy of Systemic Juvenile ArthritisJ. von Lorentz1 , A. Kropp1 , R. Häfner1 , H. Michels1
  • 1Kinderklinik, Deutsches Zentrum für Kinder- und Jugendrheumatologie, Garmisch-Partenkirchen
Further Information

Publication History

Publication Date:
27 June 2007 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Die systemische juvenile idiopathische Arthritis (SJIA), charakterisiert durch eine Arthritis, intermittierendes Fieber, flüchtiges Exanthem, generalisierte Lymphknotenschwellungen, Hepatosplenomegalie und Serositis, ist eine schwer verlaufende Erkrankung im Kindes- und Jugendalter. Antirheumatische Medikamente, die sich bei anderen Formen der JIA bewährt haben, weisen überwiegend nur eine begrenzte Wirkung auf. Dem proinflammatorische Zytokin Interleukin-1 (IL-1) konnte in der Pathogenese der SJIA eine bedeutende Rolle zugewiesen werden, was die Möglichkeit eines Einsatzes des IL-1-Rezeptorantagonisten Anakinra nahelegte. Dieses scheint sich nach den bislang vorliegenden, vorläufigen, auch eigenen Beobachtungen in begrenztem Umfang zu bestätigen. Ein wichtiger Faktor für einen Therapieerfolg scheint die Patientenauswahl zu sein. Kontrollierte Studien fehlen bislang.

Abstract

Systemic juvenile idiopathic arthritis (SJIA) is a severe disease of childhood characterized manifested by arthritis, fever, rash, generalized lymph node swelling, hepatosplenomegaly and serositis. Antirheumatic drugs show only limited effects, although they are effective for other forms of JIA. The proinflammatoric cytokine interleukin-1 (IL-1) seems to play an important role in the pathogenesis of SJIA. Therefore, it seemed reasonable to use the IL-1 receptor antagonist Anakinra in treatment of SJIA. International experiences up to now including our own results confirm a sometimes amazing efficacy of Anakinra in SJIA. An important requirement for reliable results, however, concerns the selection of patients eligible for the treatment. Controlled studies are still missing.

Schlüsselwörter

systemische juvenile idiopathische Arthritis - Anakinra - Interleukin-1

Key words

systemic juvenile idiopathic arthritis - anakinra - interleukin-1

Literatur

  • 1 Adams A, Lehman T. Update on the pathogenesis and treatment of systemic onset juvenile rheumatoid arthritis.  Curr Opin Rheumatol. 2005;  17 612-616
    Google Scholar
  • 2 Andersson G, Fasth A, Andersson J. Incidence and prevalence of juvenile rheumatoid arthritis: a population survey.  Ann Rheum dis. 1987;  46 277-281
    Google Scholar
  • 3 Bowyer S, Roettcher P, Higgins C. et al . Health status of patients with juvenile rheumatoid arthritis at 1 and 5 years after diagnosis.  J Rheumatol. 2003;  30 394-400
    Google Scholar
  • 4 Breshnihan B, Alvaro-Gracia J, Cobby M. et al . Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist.  Arthritis Rheum. 1998;  41 2196
    Google Scholar
  • 5 Calvo I, Lopez Montesenios M B, Millan M. Anakinra effectivity in systemic juvenile idiopathic arthritis non responding to conventional treatments. PRES 2005.  Clin Exp Rheumatol. 2005;  23 (Suppl 37) S 66
    Google Scholar
  • 6 De Benedetti F, Pignatti P, Massa M. et al . Circulating levels of interleukin 1β and of interleukin 1 receptor antagonist in systemic juvenile chronic arthritis.  Clin Exp Rheumatol. 1995;  13 779-784
    Google Scholar
  • 7 De Benedetti F, Pignatti P, Gerloni V. et al . Differences in synovial fluid cytokine levels between juvenile and adult rheumatoid arthritis.  J Rheumatol. 1997;  24 1403-1409
    Google Scholar
  • 8 Dayer J. Evidence for the biological modulation of IL-1 activity: The role of IL1-Ra.  Clin Exp Rheumatol. 2002;  20 (Suppl 27) S14-S20
    Google Scholar
  • 9 Genovese M, Cohen S, Moreland L. et al . Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate.  Arthritis Rheum. 2004;  50 1412-1419
    Google Scholar
  • 10 Goldbacher-Mansky R, Dailey N, Canna S. et al . Neonatal-onset multisystem inflammatory disease responsive to interleukin-1β inhibition.  N Engl J Med. 2006;  355 581-592
    Google Scholar
  • 11 Hawkins P, Lachmann H, Aganna E. et al . Spectrum of clinical features in Muckle-Wells syndrome and response to anakinra.  Arthritis Rheum. 2004;  50 607-612
    Google Scholar
  • 12 Henrickson M. Efficacy of anakinra in systemic arthritis.  Arthritis Rheum. 2004;  50 (Suppl) S 438
    Google Scholar
  • 13 Horneff G, Schmeling H, Biedermann T. et al . The german etanercept registry for treatment of juvenile idiopathic arthritis.  Ann Rheum Dis. 2004;  63 1638-1644
    Google Scholar
  • 14 Irigoyen P, Olson J, Hom C. et al . Treatment of systemic onset juvenile idiopathic arthritis with anakinra.  Pediatric Rheumatology Online Journal. 2006;  2
    Google Scholar
  • 15 Kimura Y, Pinho P, Walco G. et al . Etanercept treatment in patients with refractory systemic onset juvenile rheumatoid arthritis.  J Rheumatol. 2005;  32 935-942
    Google Scholar
  • 16 Kropp A, Kettner H, Michels M. Anakinra bei zwei Kindern mit therapieresistenter systemischer juveniler idiopathischer Arthritis.  Arthritis + Rheuma. 2006;  26 109-112
    Google Scholar
  • 17 Lomater C, Gerloni V, Gattinara M. et al . Systemic onset juvenile idiopathic arthritis: a retrospective study of 80 consecutive patients followed for 10 years.  J Rheumatol. 2000;  27 491-496
    Google Scholar
  • 18 Lovell D, Giannini E, Reiff A. et al . Etanercept in children with polyarticular juvenile rheumatoid arthritis.  N Engl J Med. 2000;  342 763-769
    Google Scholar
  • 19 Lovell D, Bowyer S, Solinger A. Interleukin-1 blockade by anakinra improves clinical symptoms in patients with neonatal-onset multisystem inflammatory disease.  Arthritis Rheum. 2005;  52 1283-1286
    Google Scholar
  • 20 Mangge H, Kenzian H, Gallistl S. et al . Serum cytokines in juvenile rheumatoid arthritis.  Arthritis Rheum. 1995;  38 211-220
    Google Scholar
  • 21 Modesto C, Saiz E, Galvez J. et al . Il-1Ra treatment in systemic onset juvenile idiopathic arthritis. Clinical and biological response. PRES 2005.  Clin Exp Rheumatol. 2005;  23 (Suppl 37) S 67
    Google Scholar
  • 22 Muzaffer M, Dayer J, Feldman B. et al . Differences in the profiles of circulating levels of soluble tumor necrosis factor receptors and interleukin 1 receptor antagonist reflect the heterogeneity of the subgroups of juvenile rheumatoid arthritis.  J Rheumatol. 2002;  29 1071-1078
    Google Scholar
  • 23 Pascual V, Allantaz F, Arce E. et al . Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade.  JEM. 2005;  201 1479-1486
    Google Scholar
  • 24 Petty R E, Cassidy J T. Systemic arthritis. Cassidy JT, Petty RE, Laxer R, Lindsley CB Textbook of Pediatric Rheumatology Philadelphia; Elsevier Saunders 2005 5. Edition: 291-303
    Google Scholar
  • 25 Petty R E, Southwood T R, Manners P. et al . International League of Association for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton 2001.  J Rheumatol. 2004;  31 390-392
    Google Scholar
  • 26 Quartier P, Kone-Paut I, Job-Deslandre C. et al . Il-1Ra (anakinra) treatment in systemic-onset juvenile idiopathic arthritis. PRES 2005.  Clin Exp Rheumatol. 2005;  23 (Suppl 37) S 65
    Google Scholar
  • 27 Ravelli A. Macrophage activation syndrome.  Curr Opin Rheumatol. 2002;  14 548-552
    Google Scholar
  • 28 Reiff A. The use of anakinra in juvenile arthritis.  Current Rheumatology Reports. 2005;  7 434-440
    Google Scholar
  • 29 Rooney M, David J, Symons J. et al . Inflammatory cytokine responses in juvenile chronic arthritis.  Br J Rheumatol. 1995;  34 454-460
    Google Scholar
  • 30 Rubbert-Roth A, Perniok A. Der Interleukin-1-Rezeptorantagonist Anakinra (Kineret®) in der Behandlung mit rheumatoider Arthritis.  Z Rheumatol. 2003;  62 367-377
    Google Scholar
  • 31 Saadeh C, Hollister R, Malacara J. et al . Successful treatment of stills disease with anakinra after failure to respond to multiple therapeutic modalities including methotrexate, infliximab, intravenous immunoglobulines, etanercept and adalinumab.  Ann Rheum Dis. 2004;  S1 63
    Google Scholar
  • 32 Spiegel R, Schneider R, Lang B. et al . Early predictors of poor functional outcome in systemic-onset juvenile rheumatoid arthritis. A multicenter corhort study.  Arthritis Rheum. 2000;  43 2402-2409
    Google Scholar
  • 33 Svantesson H, Akesson A, Eberhardt K. et al . Prognosis in juvenile rheumatoid arthritis with systemic onset. A follow-up study.  Scand J Rheumatol. 1983;  12 139
    Google Scholar
  • 34 Waugh J, Perry C M. Anakinra: a review of its use in the management of rheumatoid arthritis.  Biodrugs. 2005;  19 189-202
    Google Scholar
  • 35 Woo P, Southwood T, Prieur A. et al . Randomized, placebo-controlled, crossover trial of low-dose oral methotrexate in children with extended oligoartikulär or systemic arthritis.  Arthritis Rheum. 2000;  43 1849-1857
    Google Scholar
  • 36 Verbsky J, White A. Effective use of the recombinant interleukin 1 receptor antagonist anakinra in therapy resistant systemic onset juvenile rheumatoid arthritis.  J Rheumatol. 2004;  31 2071-2075
    Google Scholar
  • 37 Yilmaz M, Kendirli G, Altintas D. et al . Cytokine levels in serum of patients with juvenile rheumatoid arthritis.  Clin Rheumatol. 2001;  20 30-35
    Google Scholar

Dr. Johannes von Lorentz

Kinderklinik, Deutsches Zentrum für Kinder- und Jugendrheumatologie

Gehfeldstr. 24

82467 Garmisch-Partenkirchen

Phone: ++49/88 21/70 10

Fax: ++49/88 21/70 12 60

Email: j.v.lorentz@gmx.de

      >